Status:
COMPLETED
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
Galderma R&D
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
Up to 1 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic der...
Detailed Description
All neonates will be treated with Cetaphil cream starting within 1 week of birth. All neonates enrolled will have an increased risk of developing atopic dermatitis because they have a family history o...
Eligibility Criteria
Inclusion
- at least one parent diagnosed with Atopic Dermatitis
- one parent or sibling with hayfever or asthma
Exclusion
- newborns with dermatitis at birth
- newborns born greater than four weeks prematurely
- newborns with medical problems necessitating prolonged hospitalization
- newborns diagnosed with any immune deficiency syndrome
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00806221
Start Date
November 1 2006
End Date
November 1 2009
Last Update
July 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University, Department of Dermatology
Portland, Oregon, United States, 97239